Literature DB >> 16452229

P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation.

Suresh K Rayala1, Amjad H Talukder, Seetharaman Balasenthil, Robbin Tharakan, Christopher J Barnes, Rui-An Wang, C Marcelo Aldaz, Sohaib Khan, Rakesh Kumar.   

Abstract

Here, we investigated the role of P21-activated kinase 1 (Pak1) signaling in the function of estrogen receptor-alpha (ER-alpha) as assessed by serine 305 (S305) activation and transactivation activity of ER. We found that Pak1 overexpression interfered with the antiestrogenic action of tamoxifen upon the ER transactivation function in hormone-sensitive cells. In addition, tamoxifen stimulation led to up-regulation of ER target genes in breast cancer cells with increased Pak1 expression. Tamoxifen also increased Pak1-ER interaction in tamoxifen-resistant but not in tamoxifen-sensitive cells. Results from the mutational studies discovered a role of ER-S305 phosphorylation in triggering a subsequent phosphorylation of serine 118 (S118), and these effects were further potentiated by tamoxifen treatment. We found that S305 activation-linked ER transactivation function requires a functional S118, and active Pak1 signaling is required for a sustaining S118 phosphorylation of the endogenous ER. All of these events were positively influenced by tamoxifen and thus may contribute toward the loss of antiestrogenic effect of tamoxifen. These findings suggest that Pak1 signaling-dependent activation of ER-S305 leads to an enhanced S118 phosphorylation presumably due to a conformational change, and such structural modifications may participate in the development of tamoxifen resistance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16452229     DOI: 10.1158/0008-5472.CAN-05-2922

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  61 in total

Review 1.  Molecular pathways: targeting p21-activated kinase 1 signaling in cancer--opportunities, challenges, and limitations.

Authors:  Jeyanthy Eswaran; Da-Qiang Li; Anil Shah; Rakesh Kumar
Journal:  Clin Cancer Res       Date:  2012-05-17       Impact factor: 12.531

2.  Identification of phosphorylation sites in betaPIX and PAK1.

Authors:  Mark W Mayhew; Erin D Jeffery; Nicholas E Sherman; Kristina Nelson; Joy M Polefrone; Stephen J Pratt; Jeffrey Shabanowitz; J Thomas Parsons; Jay W Fox; Donald F Hunt; Alan F Horwitz
Journal:  J Cell Sci       Date:  2007-11-15       Impact factor: 5.285

3.  The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis.

Authors:  Anjali Naresh; Ann D Thor; Susan M Edgerton; Kathleen C Torkko; Rakesh Kumar; Frank E Jones
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

Review 4.  The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies.

Authors:  Anne W Hamburger
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-04-19       Impact factor: 2.673

5.  Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.

Authors:  Thomas P Ahern; Deirdre P Cronin-Fenton; Timothy L Lash; Henrik Toft Sørensen; Anne Gulbech Ording; Stephen J Hamilton-Dutoit; Ylva Hellberg
Journal:  Acta Oncol       Date:  2016-04-08       Impact factor: 4.089

6.  Signal transduction in Alzheimer disease: p21-activated kinase signaling requires C-terminal cleavage of APP at Asp664.

Authors:  Thuy-Vi V Nguyen; Veronica Galvan; Wei Huang; Surita Banwait; Huidong Tang; Junli Zhang; Dale E Bredesen
Journal:  J Neurochem       Date:  2007-11-06       Impact factor: 5.372

Review 7.  Pathways to tamoxifen resistance.

Authors:  Rebecca B Riggins; Randy S Schrecengost; Michael S Guerrero; Amy H Bouton
Journal:  Cancer Lett       Date:  2007-05-01       Impact factor: 8.679

Review 8.  Steroid receptor phosphorylation: Assigning function to site-specific phosphorylation.

Authors:  Robert D Ward; Nancy L Weigel
Journal:  Biofactors       Date:  2009 Nov-Dec       Impact factor: 6.113

9.  Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment.

Authors:  Gauri Sabnis; Olga Goloubeva; Rabia Gilani; Luciana Macedo; Angela Brodie
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

10.  Systematic mapping of posttranslational modifications in human estrogen receptor-alpha with emphasis on novel phosphorylation sites.

Authors:  Christian Atsriku; David J Britton; Jason M Held; Birgit Schilling; Gary K Scott; Bradford W Gibson; Christopher C Benz; Michael A Baldwin
Journal:  Mol Cell Proteomics       Date:  2008-11-03       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.